These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10822022)

  • 1. Response of estrogen receptor containing tumour cells to pure antiestrogens and the calmodulin inhibitor, calmidzolium chloride.
    Newton CJ; Eycott K; Green V; Atkin SL
    J Steroid Biochem Mol Biol; 2000 May; 73(1-2):29-38. PubMed ID: 10822022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor blockade by the pure antiestrogen, ZM 182780, induces death of pituitary tumour cells.
    Newton CJ
    J Steroid Biochem Mol Biol; 1995 Dec; 55(3-4):327-36. PubMed ID: 8541229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
    Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
    J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha.
    Brockdorff BL; Heiberg I; Lykkesfeldt AE
    Endocr Relat Cancer; 2003 Dec; 10(4):579-90. PubMed ID: 14713268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
    Planas-Silva MD; Waltz PK; Kilker RL
    J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):193-8. PubMed ID: 16464573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
    Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
    Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models.
    Fan P; Yue W; Wang JP; Aiyar S; Li Y; Kim TH; Santen RJ
    Endocrinology; 2009 May; 150(5):2036-45. PubMed ID: 19179445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells.
    Lazennec G; Katzenellenbogen BS
    Mol Cell Endocrinol; 1999 Mar; 149(1-2):93-105. PubMed ID: 10375022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antiestrogen ICI 182,780 inhibits proliferation of human breast cancer cells by interfering with multiple, sequential estrogen-regulated processes required for cell cycle completion.
    Cicatiello L; Addeo R; Altucci L; Belsito Petrizzi V; Boccia V; Cancemi M; Germano D; Pacilio C; Salzano S; Bresciani F; Weisz A
    Mol Cell Endocrinol; 2000 Jul; 165(1-2):199-209. PubMed ID: 10940498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens.
    Burow ME; Weldon CB; Tang Y; McLachlan JA; Beckman BS
    J Steroid Biochem Mol Biol; 2001 Nov; 78(5):409-18. PubMed ID: 11738551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer.
    Maynadier M; Basile I; Gallud A; Gary-Bobo M; Garcia M
    Oncol Rep; 2016 Aug; 36(2):1127-34. PubMed ID: 27373750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.
    Bianco NR; Perry G; Smith MA; Templeton DJ; Montano MM
    Mol Endocrinol; 2003 Jul; 17(7):1344-55. PubMed ID: 12714703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells.
    Chen X; Danes C; Lowe M; Herliczek TW; Keyomarsi K
    J Natl Cancer Inst; 2000 Sep; 92(17):1403-13. PubMed ID: 10974076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
    Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
    Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K; Curran MP; Plosker GL
    Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
    Carroll JS; Lynch DK; Swarbrick A; Renoir JM; Sarcevic B; Daly RJ; Musgrove EA; Sutherland RL
    Cancer Res; 2003 Aug; 63(15):4322-6. PubMed ID: 12907598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
    Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
    Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.